GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 09:45:43 2024-04-24 am EDT			5-day change	1st Jan Change
1,649 ^GBX	-0.11%		+4.18%	+14.23%

01:52pm	GSK : Gets a Sell rating from JP Morgan	ZD
01:38pm	GSK : Gets a Buy rating from Bernstein	ZD

GLAXOSMITHKLINE : Buy rating from Jefferies

November 18, 2020 at 03:09 pm EST

In his latest research note, analyst Peter Welford confirms his positive recommendation. The broker Jefferies is keeping its Buy rating. The target price remains set at GBX 2000.

Latest news about GSK plc

GSK : Gets a Sell rating from JP Morgan	07:52am	ZD
GSK : Gets a Buy rating from Bernstein	07:38am	ZD
GSK: FDA priority review for endometrial cancer	04:51am	CF
GSK's Jemperli with chemotherapy accepted for priority review by FDA	04:14am	AN
GSK Secures US FDA's Priority Review for Expanded Use of Endometrial Cancer Treatment	03:12am	MT
GSK Says U.S. FDA Accepts New Indication Filing For Jemperli	02:16am	RE
Edwards Lifesciences Corporation: The story continues	Apr. 23
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
GSK Reports Positive Data for Gonorrhea Treatment Gepotidacin, Shingles Vaccine Shingrix	Apr. 17	MT
GSK: positive clinical results for gonorrhea	Apr. 17	CF
Gsk plc Announces New Long-Term Data Show Shingrix Continues to Provide High Protection Against Shingles in Adults Aged 50 and over for More Than A Decade	Apr. 17	CI
GSK: shingles virus effective for over 10 years	Apr. 17	CF
GSK hails data on Shingles vaccine and gonorrhoea treatment	Apr. 17	AN
GSK's Uncomplicated Urogenital Gonorrhea Treatment Meets Primary Endpoint in Late-stage Trial	Apr. 17	MT
GSK's Shingles Vaccine Shows High Efficacy Among Older Adults in 11-Year Follow-Up Trial	Apr. 17	MT
GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin	Apr. 17	CI
China GDP Beat Fails to Boost Sentiment as UK's FTSE 100 Index Sheds Nearly 2%	Apr. 16	MT
GSK Says US FDA Accepts Meningococcal Vaccine Candidate for Regulatory Review	Apr. 16	MT
GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY Vaccine Candidate	Apr. 16	CI
GSK: vaccine accepted for FDA review	Apr. 16	CF
GSK's latest meningitis vaccine accepted for review by US regulator	Apr. 16	AN
GSK Says FDA Accepts GSK Meningitis Vaccine Candidate File	Apr. 16	RE
US FDA Accepts GSK's Meningococcal Disease Vaccine Candidate for Regulatory Review	Apr. 16	MT
Pfizer RSV shot meets goals in trial of high-risk adults under age 60	Apr. 09	RE
GSK : Barclays sticks Neutral	Apr. 08	ZD

GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.

Sector

Pharmaceuticals

Calendar

2024-04-29 - European Society of Clinical Microbiology and Infectious Diseases Meeting

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

GSK PLC : 2023 ended on a strong note; medium- to long-term guidance raised

February 02, 2024 at 09:40 am EST

More Strategies

Ratings for GSK plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

16.51 GBP

Average target price

20.06 GBP

Spread / Average Target

+21.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GSK PLC	+14.23%	83.92B
ELI LILLY AND COMPANY	+28.25%	672B
NOVO NORDISK A/S	+26.94%	570B
JOHNSON & JOHNSON	-5.34%	360B
MERCK & CO., INC.	+15.97%	321B
ABBVIE INC.	+9.39%	300B
ASTRAZENECA PLC	+7.43%	217B
ROCHE HOLDING AG	-9.20%	204B
NOVARTIS AG	+5.79%	199B
PFIZER, INC.	-8.82%	149B

Other Pharmaceuticals

GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

GLAXOSMITHKLINE : Buy rating from Jefferies

Latest news about GSK plc

Chart GSK plc

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for GSK plc

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals